New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:41 EDTARGSArgos says treatment with AGS-003, sunitinib improved expected mRCC survival
Argos Therapeutics announced updated results from a completed phase 2 study highlighting the long-term survival observed in patients treated with sunitinib combined with AGS-003, the company's investigational fully personalized immunotherapy for cancer. Results were presented in a poster presentation at the American Society of Clinical Oncology Annual Meeting on Friday, May 30. According to the results of the study titled "Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib," presented by lead author Asim Amin, MD, PhD, treatment with AGS-003 in combination with sunitinib in an unfavorable risk mRCC patient population, resulted in median progression free survival of 11.2 months and median overall survival of 30.2 months. Based upon recently published findings from the International mRCC Database Consortium, similar risk mRCC patients with a time from diagnosis to treatment of less than one year risk factor have an expected median PFS of 5.7 months and median OS of 14.7 months. In addition, 33% of patients survived for greater than 4.5 years and 23% for more than five years, with two patients remaining in long-term remission for longer than five years following continued dosing with AGS-003. Adverse events associated with the use of AGS-003 were minor with no grade 3 or 4 AEs and no evidence of autoimmunity. "These results showing the potential for AGS-003 to double the expected PFS, OS and extend long-term survival in unfavorable risk mRCC, provide strong support for the ongoing, pivotal ADAPT phase 3 trial. Our goal at Argos is to bring this promising, fully personalized immunotherapy to mRCC patients as quickly as possible to address persistent unmet needs in current standard of care," said Jeff Abbey, CEO and president of Argos Therapeutics.
News For ARGS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 14, 2015
16:16 EDTARGSArgos Therapeutics reports Q1 EPS (89c), consensus (80c)
Subscribe for More Information
15:01 EDTARGSNotable companies reporting after market close
Subscribe for More Information
May 13, 2015
17:34 EDTARGSArgos Therapeutics to present AGS-003 data at 2015 ASCO meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use